Home / Business and Economy / Symbiotec IPO Opens: Rs 1,757 Cr Issue with 41% GMP
Symbiotec IPO Opens: Rs 1,757 Cr Issue with 41% GMP
24 Aug
Summary
- Symbiotec Pharmalab's IPO is valued at Rs 1,757 crore.
- The IPO price band is set between Rs 938 and Rs 988.
- Grey market premium indicates a 41% expected listing gain.
The Symbiotec Pharmalab IPO commenced on August 24, 2026, seeking to raise Rs 1,757 crore. The issue is structured with a fresh issuance of 15 lakh shares and an offer for sale (OFS) of 1.63 crore shares, with a price band set at Rs 938-Rs 988 per share. Preliminary market sentiment is robust, reflected in a 41% grey market premium (GMP) of Rs 409, projecting an estimated listing price around Rs 1,397.
The IPO proceeds, totaling Rs 1,757 crore, will partially be used for debt reduction, with Rs 112.50 crore allocated for prepayment or repayment of select borrowings. The remainder will support general corporate purposes. Founded in 2002, Symbiotec Pharmalab specializes in manufacturing active pharmaceutical ingredients (APIs) and other biotechnological products for both domestic and international markets.
The company holds approvals from international regulatory bodies including the US FDA and EU-GMP authorities. Its manufacturing facilities possess substantial capacity for chemical synthesis and fermentation. The IPO, which closes on August 27, 2026, presents investors with an opportunity to participate in India's growing pharmaceutical and biotechnology landscape.
